Indications
Comments
Pre-clinical
P1/IIT
P2
P3
Cutaneous T Cell Lymphoma
FDA Fast Track Review and Orphan Designation supports accelerated approval and commercialization (Pivotal P2 3Q24)
3Q24
Organ transplantation (rejection prevention, LT immunotolerance)
P1: induction therapy prior to transplantation
P2: induction of stable T- and B-cell tolerance post kidney transplant (IND submission 3Q24)
P2: induction of stable T- and B-cell tolerance post kidney transplant (IND submission 3Q24)
4Q24
2Q25
GvHD
For steroid refractory GvHD patients
4Q24
Lymphodepletion for T cell cancer therapies
Potentially best-in-class lymphodepletion agent as adjunct to CAR-T and TIL therapy
Research collaboration with Moffitt
Solid tumor
Approved IND for + irradiation + anti-checkpoint inhibitors to treat melanoma
Search for IIT collaboration
AIDS: removal T cell harbored HIV reservoir
In vitro POC for lysis of HIV infected T cells and prevention of re-infection; in search of IIT partner
Search for IIT collaboration
Autoimmune Diseases (MS, T1D, RA)
Preparing pre-clinical study to ablate existing T cell population and homeostatic proliferation of new T cell population
Search for collaboration partner to evaluate development plan and initiate IIT